Real-world persistence with dupilumab among adults with atopic dermatitis
| Autor: | Debra Sierka, Jessica J. Jalbert, Cheng Chen, Haixin Zhang, Andrew Korotzer, Vera Mastey, Mandeep Kaur, Zhen Chen, Usha G. Mallya, Miriam C. Fenton, Abhijit Gadkari, Emma Guttman-Yassky, Jonathan I. Silverberg, Andreas Kuznik |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Immunology Antibodies Monoclonal Humanized Dermatitis Atopic Persistence (computer science) Patient satisfaction Internal medicine Humans Immunology and Allergy Medicine Molecular Targeted Therapy Retrospective Studies business.industry Disease Management Interleukin-4 Receptor alpha Subunit Retrospective cohort study Atopic dermatitis Middle Aged medicine.disease Dupilumab Comorbidity Confidence interval Treatment Outcome Tolerability Female Disease Susceptibility business |
| Zdroj: | Annals of Allergy, Asthma & Immunology. 126:40-45 |
| ISSN: | 1081-1206 |
| Popis: | Background The real-world persistence with dupilumab therapy for atopic dermatitis (AD) is unknown. Objective To characterize adults with AD who initiated dupilumab and evaluate persistence with dupilumab therapy. Methods This retrospective cohort study used the IBM MarketScan Commercial and Medicare database. Adults with AD who initiated dupilumab (first dispensation = index date) between March 28, 2017, and March 31, 2018, were identified and followed up until September 30, 2018, or disenrollment. Twelve months of continuous preindex enrollment were required to characterize baseline treatment history and comorbidities. Kaplan-Meier analysis was used to estimate dupilumab persistence at 6 and 12 months, assuming a 14-day injection frequency and a 30-day grace period. Results A total of 1963 adults were identified who initiated dupilumab (mean [SD] age 42.1 [15.7] years; 50.7% women; 49.8% with ≥1 atopic comorbidity). Baseline AD treatments included topical corticosteroids (81.6%), systemic corticosteroids (72.5%), and systemic immunosuppressants (22.8%). Dupilumab persistence (95% confidence interval) at 6 and 12 months was 91.9% (90.7%-93.2%) and 77.3% (75.0%-79.7%), respectively. Among 329 patients who discontinued dupilumab, the risk of reinitiation was 78.8% (95% confidence interval: 75.8%-81.7%) within an average of 4 months. Conclusion Dupilumab persistence at 12 months was high, suggesting patient satisfaction with effectiveness, tolerability, and treatment regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|